AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AROVELLA THERAPEUTICS LTD

0.077

+0.0011.32%

Volume:2.82M

Turnover:212.58K

Market Cap:91.16M

PE:-12.51

High:0.078

Open:0.078

Low:0.074

Close:0.076

Loading ...

Overview Company News Filings

Arovella Secures Option to License Cell Receptors Targeting Solid Tumours From US College

MT Newswires Live

Arovella Therapeutics Ltd-Cancel - Proposed Issue of Securities - Ala

THOMSON REUTERS

Arovella Therapeutics Ltd-Proposed Issue of Securities - Ala

THOMSON REUTERS

BRIEF-Arovella Therapeutics Announces New Placement Of About A$15 Mln At A$0.125 Per Share

Arovella Therapeutics - New Placement of Approximately a$15 Mln at a$0.125 per Share

THOMSON REUTERS

Arovella Therapeutics Ltd-Proposed Issue of Securities - Ala

THOMSON REUTERS

BRIEF-Arovella Therapeutics Seeks Trading Halt

Arovella Therapeutics to Raise AU$20 Million via Share Placement; Shares Up 7%

MT Newswires Live

BRIEF-Arovella Therapeutics To Raise A$20 Million

BUZZ-Australia's Arovella Therapeutics rises on $12.4 mln clinical trial funding

Arovella Therapeutics - Firm Commitments Received for a$20 Mln Placement at a$0.17 per Share

THOMSON REUTERS

BRIEF-Arovella Therapeutics Seeks Trading Halt

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.077,"timestamp":1749190320000,"preClose":0.076,"halted":0,"volume":2819806,"delay":0,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":890226818,"shares":1183870665,"eps":-0.006156,"marketStatus":"Market Closed","change":0.001,"latestTime":"06-06 16:12:00 AEST","open":0.078,"high":0.078,"low":0.074,"amount":212575,"amplitude":0.052632,"askPrice":0.078,"askSize":464285,"bidPrice":0.075,"bidSize":133320,"shortable":3,"etf":0,"ttmEps":-0.006156,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.076,"openAndCloseTimeList":[[1749168000000,1749189600000]],"volumeRatio":1.6567090816897971,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":890226818,"roa":"-45.61%","roe":"-85.35%","lyrEps":-0.00929,"volumeRatio":1.6567090816897971,"shares":1183870665,"dividePrice":0,"high":0.078,"amplitude":0.052632,"preClose":0.076,"low":0.074,"week52Low":0.068,"pbRate":"7.90","psRate":"26.44","week52High":0.21,"institutionHeld":0,"latestPrice":0.077,"committee":-0.553819,"eps":-0.006156,"divideRate":0,"volume":2819806,"delay":0,"ttmEps":-0.006156,"open":0.078,"prevYearClose":0.17,"prevWeekClose":0.076,"prevMonthClose":0.076,"prevQuarterClose":0.08,"fiveDayClose":0.076,"twentyDayClose":0.083,"sixtyDayClose":0.094},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533376189","title":"Arovella Secures Option to License Cell Receptors Targeting Solid Tumours From US College","url":"https://stock-news.laohu8.com/highlight/detail?id=2533376189","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533376189?lang=en_us&edition=fundamental","pubTime":"2025-05-05 12:10","pubTimestamp":1746418204,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  secured an exclusive six-month option to license chimeric antigen receptors from the Baylor College of Medicine in Texas, according to a Monday filing with the Australian bourse.The option covers two chimeric antigen receptors  targeting GD2 and GPC3, clinically validated targets in cancers such as neuroblastoma, glioma, and hepatocellular carcinoma, the filing said.If exercised, the license would allow Arovella to incorporate the CARs and additional enhancements into its allogeneic CAR-iNKT cell therapies, the filing added.No upfront fee was paid for the option. During the option period, Baylor is restrictedfrom offering the technologies to other parties in the same field, the company said.The parties intend to negotiate a definitive licence agreement if Arovella proceeds, the company added.Shares of Arovella Therapeutics rose past 2% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2524011129","title":"Arovella Therapeutics Ltd-Cancel - Proposed Issue of Securities - Ala","url":"https://stock-news.laohu8.com/highlight/detail?id=2524011129","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524011129?lang=en_us&edition=fundamental","pubTime":"2025-04-01 07:28","pubTimestamp":1743463681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUE6JQPPV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"gpt_icon":0},{"id":"2522832321","title":"Arovella Therapeutics Ltd-Proposed Issue of Securities - Ala","url":"https://stock-news.laohu8.com/highlight/detail?id=2522832321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522832321?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:01","pubTimestamp":1742943695,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUE3F9GTS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2514022161","title":"BRIEF-Arovella Therapeutics Announces New Placement Of About A$15 Mln At A$0.125 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022161","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022161?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:26","pubTimestamp":1740533183,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Announces New Placement Of About A$15 Mln At A$0.125 Per ShareFeb 26 (Reuters) - Arovella Therapeutics Ltd ALA.AX:NEW PLACEMENT OF APPROXIMATELY A$15 MILLION AT A$0.125 PER SHAREFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG16F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2514023540","title":"Arovella Therapeutics - New Placement of Approximately a$15 Mln at a$0.125 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2514023540","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514023540?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:16","pubTimestamp":1740525392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG16F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2514023545","title":"Arovella Therapeutics Ltd-Proposed Issue of Securities - Ala","url":"https://stock-news.laohu8.com/highlight/detail?id=2514023545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514023545?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:16","pubTimestamp":1740525371,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUE2HDYTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2509572182","title":"BRIEF-Arovella Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2509572182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509572182?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:25","pubTimestamp":1738794352,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Seeks Trading HaltFeb 6 (Reuters) - Arovella Therapeutics Ltd ALA.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISINGFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW23I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2502001184","title":"Arovella Therapeutics to Raise AU$20 Million via Share Placement; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502001184","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502001184?lang=en_us&edition=fundamental","pubTime":"2025-01-10 11:09","pubTimestamp":1736478567,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics  received firm commitments to raise about AU$20 million via the placement of 117.6 million shares at AU$0.17 apiece, according to a Friday filing with the Australian bourse.Proceeds will fund the first phase clinical trial for the company's cell therapy product, ALA-101, in patients with CD19-positive blood cancers, and support its solid tumor programs and pipeline expansion, the filing said.Shares rose nearly 7% in afternoon trade Friday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALA.AU","BK7096","LENZ","BK4139"],"gpt_icon":0},{"id":"2502070576","title":"BRIEF-Arovella Therapeutics To Raise A$20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2502070576","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502070576?lang=en_us&edition=fundamental","pubTime":"2025-01-10 09:22","pubTimestamp":1736472165,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics To Raise A$20 MillionJan 10 (Reuters) - Arovella Therapeutics Ltd ALA.AX:FIRM COMMITMENTS RECEIVED FOR A$20 MILLION PLACEMENT AT A$0.17 PER SHAREFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nFWN3O50N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2502074272","title":"BUZZ-Australia's Arovella Therapeutics rises on $12.4 mln clinical trial funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2502074272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502074272?lang=en_us&edition=fundamental","pubTime":"2025-01-10 08:39","pubTimestamp":1736469595,"startTime":"0","endTime":"0","summary":"** Shares of Arovella Therapeutics    rise as much as 15.7% to A$0.203, their biggest intraday pct gain since Oct 11, 2024   ** The biotech firm says it secured A$20 mln  placement funding to wrap up inaugural clinical trial of lymphoma, leukemia drug ALA-101   ** Placement is at an issue price of A$0.17 per share, representing a 2.9% discount to last trade   ** Stock hits its highest level since mid-November 2024   ** Over 4.5 mln shares change hands, 5.3x the 30-day avg   ** Stock rose 47.8% in 2024    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","XJO.AU","XKO.AU","BK7096","XAO.AU"],"gpt_icon":0},{"id":"2502078087","title":"Arovella Therapeutics - Firm Commitments Received for a$20 Mln Placement at a$0.17 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2502078087","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502078087?lang=en_us&edition=fundamental","pubTime":"2025-01-10 06:38","pubTimestamp":1736462331,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nFWN3O50N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"gpt_icon":0},{"id":"2501675636","title":"BRIEF-Arovella Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2501675636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501675636?lang=en_us&edition=fundamental","pubTime":"2025-01-08 06:17","pubTimestamp":1736288230,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Seeks Trading HaltJan 8 (Reuters) - Arovella Therapeutics ALA.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON CAPITAL RAISE AND SUBSEQUENT ISSUE OF SECURITIESFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O31Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ALA.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[]}}